Prediction of recurrence for bladder cancer by a protein signature in tissue samples

A method for predicting the risk of recurrence of bladder cancer in a subject, comprising the steps of:

• (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample from the subject;
• and
• (a) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby the risk of recurrence of bladder cancer is to be predicted.

A method for identifying a subject in need of a further bladder cancer therapy after treatment of bladder cancer, comprising the steps of:

• (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample of a subject;
• and
• (b) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby a subject in need of further bladder cancer therapy is to be identified.

A method for predicting the risk of progression of bladder cancer in a subject suffering from bladder cancer, comprising the steps of:

• (a) determining the amount of at least one biomarker selected from the biomarkers shown in Table 1 in a sample from the subject;
• and
• (b) comparing the amount of the at least one biomarker with a reference amount for the at least one biomarker, whereby the risk of progression of bladder cancer is to be predicted.

A device for predicting recurrence of bladder cancer in a sample of a subject comprising:

• (a) an analyzing unit for the sample of the subject comprising a detection agent for at least one biomarker as shown in Table 1, wherein the detection agent allows for the determination of the amount of the at least one biomarker in the sample;
• and
• (b) an evaluation unit, which is operatively linked to the analyzing unit, wherein the evaluation unit comprises a data processing unit and a data base, wherein the data base comprises a stored reference and the data processing unit is capable of carrying out a comparison of the amount of the at least one biomarker determined by the analyzing unit and the stored reference, thereby establishing the prediction.

A kit comprising (i) a detection agent for determining an amount of at least one biomarker as shown in Table 1, and (ii) evaluation instructions for establishing a diagnosis.

A composition comprising a detection agent which specifically binds to the biomarker LMNA (human Lamin A), a detection agent which specifically binds to the biomarker YBOX1 (Nuclease-sensitive element-binding protein 1), and a detection agent which specifically binds to the biomarker JUN (Transcription factor AP-1).